Construction and characterization of bicistronic retroviral vectors encoding the multidurg transporter and β-galactosidase or green fluorescent protein

Cancer Gene Therapy

Volumn 5, Issue 4, 1998, Pages 195-206

  Aran, Josep M ^a   Gottesman, Michael M ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

galactosidase; GFP; P glycoprotein; Retroviral vector

Indexed keywords

BETA GALACTOSIDASE; GLYCOPROTEIN P; GREEN FLUORESCENT PROTEIN; PHOTOPROTEIN; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; CELL LINE; CELL STRAIN 3T3; GENE VECTOR; GENETICS; METABOLISM; MOUSE; RETROVIRUS; VIROLOGY;

3T3 CELLS; ANIMALS; BETA-GALACTOSIDASE; CELL LINE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LUMINESCENT PROTEINS; MICE; P-GLYCOPROTEIN; RECOMBINANT PROTEINS; RETROVIRIDAE;

EID: 0032113403     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427.
2. Gottesman MM, Hrycyna, CA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet. 1995;29: 607-649.
3. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990;42: 155-199.
4. Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. Cytotechnology. 1993;12:171-212.
5. Gottesman MM, Pastan I. The multidrug resistance (MDR1) gene as a selectable marker in gene therapy. In: Cohen-Haguenauer O., Boiron M., eds. Human Gene Transfer. Paris: Colloque INSERM/John Libbey Eurotext Ltd. 1991;219:185-191.
6. Aran JM, Gottesman MM, Pastan I. Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA. 1994; 91:3176-3180.
7. Aran JM, Licht T, Gottesman MM, Pastan I. Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy. Hum Gene Ther. 1996;7:2165-2175.
8. Sugimoto Y, Aksentijevich I, Murray GJ, et al. Retroviral coexpression of a multidrug resistance gene (MDR 1) and human a-galactosidase A for gene therapy of Fabry disease. Hum Gene Ther. 1995;6:905-915.
9. Galski H, Sullivan M, Willingham MC, et al. Expression of a human multidrug resistance cDNA (MDR 1) in the bone marrow of transgenic mice: resistance to daunomycininduced leukopenia. Mol Cell Biol. 1989;9:4357-4363.
10. Mickisch GH, Merlino GT, Galski H, et al. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA. 1991;88: 547-551.
11. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science. 1992;257:99-103.
12. Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA. 1992;89:9676-9680.
13. Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther. 1994;1:21-25.
14. Zolotukhin S, Potter M, Hauswirth WW, et al. A "humanized" green fluorescent protein cDNA adapted for high level expression in mammalian cells. J Virol 1996;70:4646-4654.
15. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA. 1988;85:4486-4490.
16. Metz MZ, Best DM, Kane SE. Harvey murine sarcoma virus/MDR1 retroviral vectors: efficient virus production and foreign gene transduction using MDR1 as a selectable marker. Virology. 1995;208:634-643.
17. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol. 1986;6:2895-2902.
18. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol. 1988;62:1120-1124.
19. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA. 1988;85: 6460-6464.
20. Aran JM, Germann UA, Gottesman MM, Pastan I. Construction and characterization of a selectable multidrug resistance-glucocerebrosidase fusion gene. Cytokines Mol Ther. 1996;2:47-57.
21. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature. 1985;316:820-823.
22. Friedmann T. Progress toward human gene therapy. Science. 1989;244:1275-1281.
23. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther. 1994;1:51-64.
24. Hoeben RC, Migchielsen AA, van der Jagt RC, et al. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol. 1991;65:904-912.
25. Kim DG, Kang HM, Jang SK, Shin HS. Construction of a bifunctional mRNA in the mouse by using the internal ribosomal entry site of the encephalomyocarditis virus. Mol Cell Biol. 1992;12:3636-3643.
26. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA.. 1986;83:7785-7789.
27. Alam J, Cook JL. Reporter genes: application to the study of mammalian gene transcription. Anal Biochem. 1990; 188:245-254.
28. Ellis RW, DeFeo D, Maryak JM, et al. Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol. 1980;36:408-420.
29. Torrent C, Gabus C, Darlix J-L. A small and efficient dimerization/packaging signal of rat VL30 RNA and its use in murine leukemia virus VL30-derived vectors for gene transfer. J Virol. 1994;68:661-667.
30. Velu TJ, Vass WC, Lowy DR, Tambourin PE. Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation in vitro and oncogenicity in vivo. J Virol. 1989;63:1384-1392.
31. Davies RL, Fuhrer-Krusi S, Kucherlapati R. Modulation of transfected gene expression mediated by changes in chromatin structure. Cell. 1982;31:521-529.
32. Freinstein SC, Ross SR, Yamamoto K. Chromosome position effects determine transcriptional potential of integrated mammary tumor virus DNA. J Mol Biol. 1982; 156:549-565.
33. Sorrentino BP, McDonagh KT, Woods D, Orlic D. Expression of retroviral vectors containing the human MDR1 cDNA in hematopoietic cells of transplanted mice. Blood. 1995;86:491-501.
34. Cheng L, Fu J, Tsukamoto A, Hawley RG. Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells. Nat Biotechnol. 1996;14: 606-609.
35. Levy JP, Muldoon RR, Zolotukhin RR, Link CJ, Jr. Retroviral transfer and expression of a humanized, redshifted green fluorescent protein gene into human tumor cells. Nat Biotechnol. 1996;14:610-614.
36. Yang F, Moss LG, Phillips GN, Jr. The molecular structure of green fluorescent protein. Nat Biotechnol 1996;14: 1246-1251.
37. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85-94.
38. Hanania EG, Fu S, Zu S, et al. Chemotherapy resistance to Taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther. 1995;2:285-294.
39. Hanania EG, Giles RE, Kavanagh J, et al. Results of MDR-1 vector modification trial indicate that granulocyte/ macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA. 1996;93:15346-15351.